Antifungal drug resistance of pathogenic fungi

Kontoyiannis, Dimitrios P; Lewis, Russell E

doi:10.1016/s0140-6736(02)08162-x

Cited by 553Antifungal resistance and susceptibilityFungal Plant Pathogen ControlFungal Infections and Studies

Antifungal drug resistance of pathogenic fungi

Kontoyiannis, Dimitrios P, Lewis, Russell E·2002·The Lancet

DOI 10.1016/s0140-6736(02)08162-x

Open this paper in CoChat — free account

Abstract

Pathogenic fungi have many complex mechanisms of resistance to antifungal drugs. Information about the clinical, cellular, and molecular factors contributing to antifungal-drug resistance continues to accumulate. We critically review the diagnosis, epidemiology, and mechanisms of antifungal drug resistance of pathogenic fungi. Better understanding of this resistance should assist in developing better detection strategies for preventing and treating refractory mycoses in the future.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(02)08162-x

Cites

118 of 118 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Azole antifungals inhibit the cytochrome P450 enzyme lanosterol demethylase, a critical enzyme in ergosterol synthesis encoded by ERG11.
“The azole class of antifungals work by inhibiting the cytochrome P450 enzyme lanosterol demethylase, a critical enzyme in the synthesis of ergosterol which is encoded by the ERG11 gene (14).”
From Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans (2012) · cites this paper as [14]
A significant proportion of isolates of C. glabrata and C. krusei species resistant to amphotericin B has been reported.
“In fact, a significant proportion of isolates of C. glabrata and C. krusei species resistant to amphotericin B has been reported [126].”
From CandidaInfections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [126]

National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736 · see citing works
Infectious Diseases Society of America
Enders, J. F. (1969) · The Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,305 · see citing works
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307 · see citing works
Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,788 · see citing works
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387 · see citing works
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353 · see citing works
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137 · see citing works
Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937 · see citing works
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 879 · see citing works
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855 · see citing works
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · see citing works
Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals
Shlaes, D. M., Gerding, D. N., John, J. F., Craig, W. A., Bornstein, D. L., Duncan, R. A., Eckman, M. R., Farrer, W. E., Greene, W. H., Lorian, V., et al. (1997) · Clinical Infectious Diseases · doi:10.1086/513766 · Cited by 781 · see citing works
Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657 · see citing works
Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612 · see citing works
Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587 · see citing works
Itraconazole resistance in Aspergillus fumigatus
Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J., Manning, N. J., Stevens, D. A., Warnock, D. W., & Kelly, S. L. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1364 · Cited by 507 · see citing works
Nosocomial Candidiasis: Emerging Species, Reservoirs, and Modes of Transmission
Pfaller, M. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s89 · Cited by 499 · see citing works
Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals
Prasad, R., De Wergifosse, P., Goffeau, A., & Balzi, E. (1995) · Current Genetics · doi:10.1007/bf00352101 · Cited by 486 · see citing works
Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · see citing works
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444 · see citing works
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404 · see citing works
Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
Sanglard, D., Ischer, F., Monod, M., & Billé, J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.10.2300 · Cited by 402 · see citing works
Safety, Tolerance, and Pharmacokinetics of High-Dose Liposomal Amphotericin B (AmBisome) in Patients Infected with Aspergillus Species and Other Filamentous Fungi: Maximum Tolerated Dose Study
Walsh, T. J., Goodman, J. L., Pappas, P. G., Bekersky, I., Buell, D. N., Roden, M. M., Barrett, J., & Anaissie, E. J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3487-3496.2001 · Cited by 401 · see citing works
Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377 · see citing works
ANTIBIOTICS THAT INHIBIT FUNGAL CELL WALL DEVELOPMENT
Debono, M., & Gordee, R. S. (1994) · Annual Review of Microbiology · doi:10.1146/annurev.mi.48.100194.002351 · Cited by 371 · see citing works
Resistance to fluconazole and cross‐resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6‐desaturation
Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351 · see citing works
The Ins and Outs of DNA Fingerprinting the Infectious Fungi
Soll, D. R. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.332-370.2000 · Cited by 348 · see citing works
The ATP Binding Cassette Transporter Gene CgCDR1 from Candida glabrata Is Involved in the Resistance of Clinical Isolates to Azole Antifungal Agents
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · see citing works
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase
Kurtz, M., Heath, I. B., Marrinan, J. A., Dreikorn, S., Onishi, J. C., & Douglas, C. M. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1480 · Cited by 321 · see citing works
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B
Walsh, T. J., MELCHER, G. P., Rinaldi, M. G., Lecciones, J., McGough, D. A., Kelly, P. M., Lee, J. K., Callender, D. P., Rubin, M., & Pizzo, P. A. (1990) · Journal of Clinical Microbiology · doi:10.1128/jcm.28.7.1616-1622.1990 · Cited by 310 · see citing works
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group
Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.40 · Cited by 300 · see citing works
Antifungal drug resistance in pathogenic fungi.
BOSSCHE, H. V., Dromer, F., Improvisi, I., Lozano‐Chiu, M., Rex, J. H., & Sanglard, D. (1998) · PubMed · Cited by 290 · see citing works
Molecular mechanisms of drug resistance in fungi
BOSSCHE, H. V., Marichal, P., & Odds, F. C. (1994) · Trends in Microbiology · doi:10.1016/0966-842x(94)90618-1 · Cited by 255 · see citing works
Role of ATP-Binding-Cassette Transporter Genes in High-Frequency Acquisition of Resistance to Azole Antifungals in Candida glabrata
Sanglard, D., Ischer, F., & Bille, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1174-1183.2001 · Cited by 247 · see citing works
Incidence of polyene-resistant yeasts recovered from clinical specimens
Dick, J. D., Merz, W. G., & Saral, R. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.18.1.158 · Cited by 242 · see citing works
Evolving Role of Flucytosine in Immunocompromised Patients: New Insights into Safety, Pharmacokinetics, and Antifungal Therapy
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232 · see citing works
Amphotericin B-resistant yeast infection in severely immunocompromised patients
Powderly, W. G., Kobayashi, G. S., Herzig, G. P., & Medoff, G. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90059-9 · Cited by 232 · see citing works
Do In Vitro Susceptibility Data Predict the Microbiologic Response to Amphotericin B? Results of a Prospective Study of Patients withCandidaFungemia
Nguyen, M. H., Clancy, C. J., Yu, V. L., Yu, Y. C., Morris, A. J., Snydman, D. R., Sutton, D. A., & Rinaldi, M. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/514193 · Cited by 219 · see citing works
Mechanism of Fluconazole Resistance in Candida krusei
Orozco, A. S., Higginbotham, L. M., Hitchcock, C. A., Parkinson, T., Falconer, D., Ibrahim, A. S., Ghannoum, M. A., & Filler, S. G. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2645 · Cited by 218 · see citing works
Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States
Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., & Hajjeh, R. A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00160-6 · Cited by 216 · see citing works
Molecular biological characterization of an azole-resistant Candida glabrata isolate
Marichal, P., Vanden Bossche, H., Odds, F. C., Nobels, G., Warnock, D. W., Timmerman, V, Van Broeckhoven, C., Fay, S., & Mose-Larsen, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2229 · Cited by 210 · see citing works
Distinct Patterns of Gene Expression Associated with Development of Fluconazole Resistance in Serial Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis
Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White, T. C., Sanglard, D., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2932 · Cited by 210 · see citing works
The Effect of Prophylactic Fluconazole on the Clinical Spectrum of Fungal Diseases in Bone Marrow Transplant Recipients with Special Attention to Hepatic Candidiasis: An Autopsy Study of 355 Patients
van Burik, J. H., Leisenring, W. M., Myerson, D., Hackman, R. C., Shulman, H. M., Sale, G. E., Bowden, R. A., & McDonald, G. B. (1998) · Medicine · doi:10.1097/00005792-199807000-00003 · Cited by 204 · see citing works
Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility
Geber, A., Hitchcock, C. A., Swartz, J. E., Pullen, F. S., Marsden, K. E., Kwon-Chung, K. J., & Bennett, J. E. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2708 · Cited by 203 · see citing works
Identification and Expression of Multidrug Transporters Responsible for Fluconazole Resistance in Candida dubliniensis
Moran, G. P., Sanglard, D., Donnelly, S. M., Shanley, D. B., Sullivan, D. J., & Coleman, D. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1819 · Cited by 197 · see citing works
Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model
Andes, D., Stamsted, T., & Conklin, R. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.922-926.2001 · Cited by 180 · see citing works
Correlation of Fluconazole MICs with Clinical Outcome in Cryptococcal Infection
Aller, A. I., Martín‐Mazuelos, E., Lozano, F., Gómez-Mateos, J. M., Steele‐Moore, L., Holloway, W. J., Gutiérrez, M. J., Recio, F., & Espinel-Ingroff, A. V. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1544-1548.2000 · Cited by 171 · see citing works
Antifungal Drug Resistance in Aspergillus
Moore, C. B., Sayers, N. M., Mosquera, J., Slaven, J. W., & Denning, D. W. (2000) · Journal of Infection · doi:10.1053/jinf.2000.0747 · Cited by 162 · see citing works
Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome
Ghannoum, M. A., Rex, J. H., & Galgiani, J. N. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.3.489-495.1996 · Cited by 159 · see citing works
Burden of aspergillosis-related hospitalizations in the United States
Dasbach, E. J., Davies, G. M., & Teutsch, S. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317487 · Cited by 159 · see citing works
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis
Louie, A., Drusano, G. L., Banerjee, P., Liu, Q.-F., Liu, W., Kaw, P., Shayegani, M., Taber, H., & Miller, M. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1105 · Cited by 154 · see citing works
Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B
Harousseau, J., Dekker, A. W., Stamatoullas, A., Fassas, Α., Linkesch, W., Gouveia, J., Bock, R. D., Rovira, M., Seifert, W., Joosen, H., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1887-1893.2000 · Cited by 154 · see citing works
Antifungal Resistance Trends Towards the Year 2000: Implications for Therapy and New Approaches
Alexander, B. D., & Perfect, J. R. (1997) · Drugs · doi:10.2165/00003495-199754050-00002 · Cited by 153 · see citing works
Editorial Response: The Contribution of Fluconazole to the Changing Epidemiology of Invasive Candidal Infections
White, M. H. (1997) · Clinical Infectious Diseases · doi:10.1086/513661 · Cited by 151 · see citing works
Risk Factors for Fluconazole-Resistant Candidiasis in Human Immunodeficiency Virus-Infected Patients
Maenza, J. R., Keruly, J. C., Moore, R. D., Chaisson, R. E., Merz, W. G., & Gallant, J. E. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/173.1.219 · Cited by 150 · see citing works
Update on antifungals targeted to the cell wall: focus on β-1,3-glucan synthase inhibitors
Georgopapadakou, N. H. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.2.269 · Cited by 149 · see citing works
Acquired itraconazole resistance in Aspergillus fumigatus
Dannaoui, É. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.3.333 · Cited by 145 · see citing works
Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750
Barchiesi, F., Calabrese, D., Sanglard, D., Falconi Di Francesco, L., Caselli, F., Giannini, D., Giacometti, A., Gavaudan, S., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1578-1584.2000 · Cited by 145 · see citing works
Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene
Ben-Yaacov, R., Knoller, S., Caldwell, G. A., Becker, J. M., & Koltin, Y. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.648 · Cited by 144 · see citing works
Specific Chromosome Alterations in Fluconazole-Resistant Mutants of Candida albicans
Perepnikhatka, V. I., Fischer, F. J., Niimi, M., Baker, R. A., Cannon, R. D., Wang, Y.-K., Sherman, F., & Rustchenko, E. P. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.13.4041-4049.1999 · Cited by 141 · see citing works
Heteroresistance to Fluconazole and Voriconazole in Cryptococcus neoformans
Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., & Kwon-Chung, K. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1856 · Cited by 139 · see citing works
High prevalence of antifungal resistance in Candida spp. from patients with AIDS
Law, D., Moore, C. B., Wardle, H. M., Ganguli, L. A., Keaney, M. G. L., & Denning, D. W. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/34.5.659 · Cited by 139 · see citing works
Genes encoding multiple drug resistance-like proteins in Aspergillus fumigatus and Aspergillus flavus
Tobin, M. B., Peery, R. B., & Skatrud, P. L. (1997) · Gene · doi:10.1016/s0378-1119(97)00281-3 · Cited by 129 · see citing works
Rationale for Combination Antifungal Therapy
Lewis, R. E., & Kontoyiannis, D. P. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.12.149s.34505 · Cited by 116 · see citing works
Self-citation
The past, present and future of antimycotic combination therapy
Polak, A. (1999) · Mycoses · doi:10.1046/j.1439-0507.1999.00475.x · Cited by 114 · see citing works
Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B
Sokol-Anderson, M., Sligh, J. E., Elberg, S., Brajtburg, J., Kobayashi, G. S., & Medoff, G. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.5.702 · Cited by 113 · see citing works
Inducible Azole Resistance Associated with a Heterogeneous Phenotype in Candida albicans
Marr, K. A., Lyons, C. N., Ha, K. C., Rustad, T. R., & White, T. C. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.52-59.2001 · Cited by 106 · see citing works
Drug resistance in Cryptococcus neoformans
Perfect, J. R., & Cox, G. M. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0090 · Cited by 106 · see citing works
Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole
Casadevall, A., Spitzer, E. D., Webb, D., & Rinaldi, M. G. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.6.1383 · Cited by 104 · see citing works
Declining Rates of Oropharyngeal Candidiasis and Carriage ofCandida albicansAssociated with Trends Toward Reduced Rates of Carriage of Fluconazole‐ResistantC. albicansin Human Immunodeficiency Virus –Infected Patients
Martins, M. D., Lozano‐Chiu, M., & Rex, J. H. (1998) · Clinical Infectious Diseases · doi:10.1086/515006 · Cited by 103 · see citing works
Combination Immunotherapy and Antifungal Chemotherapy
Stevens, D. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516362 · Cited by 100 · see citing works
Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14alpha-demethylase gene, pdmA
Osherov, N. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.1.75 · Cited by 96 · see citing works
Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains
Löffler, J., Einsele, H., Hebart, H. F., Schumacher, U., Hrastnik, C., & Daum, G. ⁄. N. (2000) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2000.tb09040.x · Cited by 92 · see citing works
High-Frequency, In Vitro Reversible Switching of Candida lusitaniae Clinical Isolates from Amphotericin B Susceptibility to Resistance
Yoon, S. A., Vázquez, J. A., Steffan, P. E., Sobel, J. D., & Akins, R. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.836 · Cited by 90 · see citing works
Correlation between In Vitro Susceptibility Determined by E Test and Response to Therapy with Amphotericin B: Results from a Multicenter Prospective Study of Candidemia
Clancy, C. J., & Nguyen, M. H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1289 · Cited by 89 · see citing works
Effects of Fluconazole Administration in Critically Ill Patients
Rocco, T. R. (2000) · Archives of Surgery · doi:10.1001/archsurg.135.2.160 · Cited by 88 · see citing works
Alteration of Cell Wall Composition Leads to Amphotericin B Resistance in Aspergillus flavus
Seo, K., Akiyoshi, H., & Ohnishi, Y. (1999) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1999.tb01231.x · Cited by 88 · see citing works
The Genetic Basis of Resistance to 5-Fluorocytosine in Candida Species and Cryptococcus Neoformans
Whelan, W. L. (1987) · CRC Critical Reviews in Microbiology · doi:10.3109/10408418709104447 · Cited by 88 · see citing works
In-vivo selection of an azole-resistant petite mutant of Candida glabrata
BOUCHARA, J.-P., LE BOUDOUIL, S., FILMON, R., ZOUHAIR, R., HALLET, J.-N., CHABASSE, D., RENIER, G., & DEFONTAINE, A. (2000) · Journal of Medical Microbiology · doi:10.1099/0022-1317-49-11-977 · Cited by 88 · see citing works
Elevated Phenotypic Switching and Drug Resistance of Candida albicans from Human Immunodeficiency Virus-Positive Individuals prior to First Thrush Episode
Vargas, K. G., Messer, S. A., Pfaller, M. A., Lockhart, S. R., Stapleton, J. T., Hellstein, J. H., & Soll, D. R. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.10.3595-3607.2000 · Cited by 86 · see citing works
The Evolution ofCandidaSpecies and Fluconazole Susceptibility among Oral and Vaginal Isolates Recovered from Human Immunodeficiency Virus (HIV)–Seropositive and At‐Risk HIV‐Seronegative Women
Sobel, J. D., Ohmit, S. E., Schuman, P. C., Klein, R. S., Mayer, K. H., Duerr, A. C., Vázquez, J. A., & Rompalo, A. M. (2001) · The Journal of Infectious Diseases · doi:10.1086/317936 · Cited by 83 · see citing works
Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe Candida Infections Treated with Fluconazole
Lee, S.-C., Fung, C., Huang, J., Tsai, C.-J., Chen, K.-S., Chen, H.-Y., Lee, N., See, L., & Wb, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2715-2718.2000 · Cited by 81 · see citing works
The Potential Role of Cytokine Therapy for Fungal Infections in Patients with Cancer: Is Recovery from Neutropenia all that is Needed?
Rodríguez-Adrián, L. J., Grazziutti, M., Rex, J. H., & Anaissie, E. J. (1998) · Clinical Infectious Diseases · doi:10.1086/516364 · Cited by 79 · see citing works
Transcriptional Analyses of Antifungal Drug Resistance in Candida albicans
Lyons, C. N., & White, T. C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2296-2303.2000 · Cited by 79 · see citing works
Azole resistance inCandida
Denning, D. W., Baily, G. G., & Hood, S. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01695630 · Cited by 75 · see citing works
Refractory Mucosal Candidiasis in Patients with Human Immunodeficiency Virus Infection
Fichtenbaum, C. J., & Powderly, W. G. (1998) · Clinical Infectious Diseases · doi:10.1086/514571 · Cited by 74 · see citing works
The Exciting Future of Antifungal Therapy
Neely, M. N., & Ghannoum, M. A. (2000) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960000395 · Cited by 71 · see citing works
Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains
Löffler, J. (2000) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(00)00071-9 · Cited by 70 · see citing works
Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans
Forgács, K., Gyüre, L., & Lenkey, B. (2000) · Mycoses · doi:10.1046/j.1439-0507.2000.00587.x · Cited by 69 · see citing works
Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum
Wheat, J., Marichal, P., BOSSCHE, H. V., LeMonte, A. M., & Connolly, P. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.410 · Cited by 68 · see citing works
Reversible fluconazole resistance in Candida albicans: a potential in vitro model
Calvet, H. M., Yeaman, M. R., & Filler, S. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.535 · Cited by 68 · see citing works
Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis
Cartledge, J. D., Midgley, J., & Gazzard, B. (1997) · AIDS · doi:10.1097/00002030-199715000-00008 · Cited by 67 · see citing works
The epidemiology of non‐albicans Candida in oropharyngeal candidiasis in HIV patients
Redding, S. W., Kirkpatrick, W. R., Dib, O. P., Fothergill, A. W., Rinaldi, M. G., & Patterson, T. F. (2000) · Special Care in Dentistry · doi:10.1111/j.1754-4505.2000.tb00015.x · Cited by 66 · see citing works
Safety and Toxicokinetics of Intravenous Liposomal Amphotericin B (AmBisome ®) in Beagle Dogs
Bekersky, I., Boswell, G. W., Hiles, R., Fielding, R. M., Buell, D. N., & Walsh, T. J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018997730462 · Cited by 64 · see citing works
In Vitro Susceptibilities of Candida and Cryptococcus neoformans Isolates from Blood Cultures of Neutropenic Patients
Hoban, D. J., Zhanel, G. G., & Karlowsky, J. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1463 · Cited by 64 · see citing works
Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis
Lynch, M. E., Sobel, J. D., & Fidel, P. L. (1996) · Medical Mycology · doi:10.1080/02681219680000571 · Cited by 63 · see citing works
Fluconazole versus Candida albicans : A Complex Relationship
Graybill, J. R., Montalbo, E. M., Kirkpatrick, W. R., Luther, M. F., Revankar, S. G., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2938 · Cited by 59 · see citing works
Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance
Venkateswarlu, K., Denning, D. W., Manning, N. J., & Kelly, S. L. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.11.2443 · Cited by 58 · see citing works
Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates
Pfaller, M. A., Messer, S. A., Bolmström, A., Odds, F. C., & Rex, J. H. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.7.1691-1693.1996 · Cited by 58 · see citing works
Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection
Tumbarello, M., Caldarola, G., Tacconelli, E., Morace, G., Posteraro, B., Cauda, R., & Ortona, L. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.4.691 · Cited by 57 · see citing works
Cross-Resistance of Clinical Isolates of Candida albicans and Candida glabrata to Over-the-Counter Azoles Used in the Treatment of Vaginitis
Cross, E. W., Park, S., & Perlin, D. S. (2000) · Microbial Drug Resistance · doi:10.1089/107662900419474 · Cited by 56 · see citing works
The Role ofCandida dubliniensisin Oral Candidiasis in Human Immunodeficiency Virus-Infected Individuals
Schorling, S., Kortinga, H. C., Froschb, M., et al. (2000) · Critical Reviews in Microbiology · doi:10.1080/10408410091154183 · Cited by 55 · see citing works
High‐dose therapy with fluconazole ≥ 800 mg day ‐1
Duswald, K. H., Penk, A., & Pittrow, L. B. (1997) · Mycoses · doi:10.1111/j.1439-0507.1997.tb00231.x · Cited by 53 · see citing works
Decreased activity of UMP pyrophosphorylase associated with resistance to 5-fluorocytosine in Candida albicans
Whelan, W. L., & Kerridge, D. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.26.4.570 · Cited by 53 · see citing works
Antagonism of Azole Activity againstCandida albicansfollowing Induction of Multidrug Resistance Genes by Selected Antimicrobial Agents
Henry, K. W., Cruz, M. C., Katiyar, S. K., & Edlind, T. D. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.8.1968 · Cited by 53 · see citing works
Predictors of outcome in cancer patients with candidemia
Uzun, Ö., & Anaissie, E. J. (2000) · Annals of Oncology · doi:10.1023/a:1008308923252 · Cited by 41 · see citing works
Comparison of the Efficacy of Polyenes and Triazoles against Hematogenous Candida krusei Infection in Neutropenic Mice
Karyotakis, N. C., Anaissie, E. J., Hachem, R., Dignani, M. C., & Samonis, G. (1993) · Journal of Infectious Diseases · doi:10.1093/infdis/168.5.1311 · Cited by 40 · see citing works
In Vivo Virulence ofCandida albicansIsolates Causing Mucosal Infections in People Infected with the Human Immunodeficiency Virus
Taylor, B. N., Fichtenbaum, C. J., Saavedra, M. C., Slavinsky, J., Swoboda, R., Wozniak, K. L., Arribas, A. R., Powderly, W. G., & Fidel, P. L. (2000) · The Journal of Infectious Diseases · doi:10.1086/315768 · Cited by 37 · see citing works
Dynamic and Heterogeneous Mutations to Fluconazole Resistance in Cryptococcus neoformans
Xu, J., Onyewu, C., Yoell, H. J., Ali, R. Y., Vilgalys, R. J., & Mitchell, T. G. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.420-427.2001 · Cited by 34 · see citing works
Genotypic identification of sequentialCandida albicans isolates from AIDS patients by polymerase chain reaction techniques
Barchiesi, F., Francesco, L. F. D., Compagnucci, P., et al. (1997) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02447925 · Cited by 32 · see citing works
A Clinical Perspective for the Management of Invasive Fungal Infections: Focus on IDSA Guidelines
Kontoyiannis, D. P. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.12.175s.34506 · Cited by 29 · see citing works
Self-citation
Fluconazole-Resistant Cryptococcus neoformans Isolated from an Immunocompetent Patient without Prior Exposure to Fluconazole
Orni‐Wasserlauf, R., Izkhakov, E., Siegman‐Igra, Y., Bash, E., Polacheck, I., & Giladi, M. (1999) · Clinical Infectious Diseases · doi:10.1086/313546 · Cited by 28 · see citing works
Antifungal chemotherapy — Are we winning?
Polak, A., & HARTMAN, P. G. (1991) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7139-6_5 · Cited by 27 · see citing works
Development of Secondary Resistance to Fluconazole in Cryptococcus neoformans Isolated from a Patient with AIDS
Alves, S. H., Lopes, J. O., Costa, J. M., et al. (1997) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s0036-46651997000600010 · Cited by 25 · see citing works
Transmission of an Azole-Resistant Isogenic Strain of Candida albicans among Human Immunodeficiency Virus-Infected Family Members with Oropharyngeal Candidiasis
Müller, F. C., Kasai, M., Francesconi, A., et al. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.10.3405-3408.1999 · Cited by 22 · see citing works
Genetically Controlled Cross Resistance to Polyene Antibiotics in Saccharomyces cerevisiae
Woods, R. A., & AHMED, K. A. (1968) · Nature · doi:10.1038/218369a0 · Cited by 17 · see citing works
Introduction: Immunomodulation for the Treatment of Invasive Fungal Infections
Anaissie, E. J. (1998) · Clinical Infectious Diseases · doi:10.1086/516359 · Cited by 9 · see citing works
Increased Adherence of Fluconazole-Resistant Isolates of Candida Species to Explanted Esophageal Mucosa
Lyman, C. A., Garrett, K. F., Peter, J., et al. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050262 · Cited by 8 · see citing works

Flagged first, then by citations

Sorted by citations

Epidemiology of Candida species infections in critically ill non-immunosuppressed patients
Eggimann, P., Garbino, J., & Pittet, D. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00801-6 · Cited by 900 · see citing works
Transcriptional Response of Candida albicans upon Internalization by Macrophages
Lorenz, M. C., Bender, J. A., & Fink, G. R. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.5.1076-1087.2004 · Cited by 712 · see citing works
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608 · see citing works
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444 · see citing works
CandidaInfections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents
Spampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411 · see citing works
Quantitation of Ergosterol Content: Novel Method for Determination of Fluconazole Susceptibility of Candida albicans
Arthington-Skaggs, B. A., Jradi, H., Desai, T., & Morrison, C. J. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.10.3332-3337.1999 · Cited by 365 · see citing works
Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence
Sanglard, D., Ischer, F., Marchetti, O., Entenza, J., & Bille, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03495.x · Cited by 350 · see citing works
Antifungal Agents
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351 · see citing works
The ATP Binding Cassette Transporter Gene CgCDR1 from Candida glabrata Is Involved in the Resistance of Clinical Isolates to Azole Antifungal Agents
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · see citing works
Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001‐2007): Stable incidence but changing epidemiology of a still frequently lethal infection
Sipsas, N. V., Lewis, R. E., Tarrand, J., Hachem, R., Rolston, K. V., Raad, I. I., & Kontoyiannis, D. P. (2009) · Cancer · doi:10.1002/cncr.24507 · Cited by 269 · see citing works
Self-citation
CRYPTIC SPECIATION IN THE COSMOPOLITAN AND CLONAL HUMAN PATHOGENIC FUNGUS ASPERGILLUS FUMIGATUS
Pringle, A., Baker, D. M., Platt, J. L., Wares, J. P., Latgé, J. P., & Taylor, J. W. (2005) · Evolution · doi:10.1111/j.0014-3820.2005.tb01059.x · Cited by 267 · see citing works
Gain-of-Function Mutations in UPC2 Are a Frequent Cause of ERG11 Upregulation in Azole-Resistant Clinical Isolates of Candida albicans
Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00215-12 · Cited by 239 · see citing works
Genomic Profiling of the Response of Candida albicans to Itraconazole Treatment Using a DNA Microarray
De Backer, M. D., Ilyina, T., Ma, X.-J., Vandoninck, S., Luyten, W. H. M. L., & Vanden Bossche, H. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1660-1670.2001 · Cited by 211 · see citing works
Structural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14α-Demethylase
Sagatova, A. A., Keniya, M. V., Wilson, R. K., Monk, B. C., & Tyndall, J. D. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-15 · Cited by 210 · see citing works
Genome-wide expression profiling of the response to polyene, pyrimidine, azole, and echinocandin antifungal agents in Saccharomyces cerevisiae.
Agarwal, A. K., Rogers, P. D., Baerson, S. R., Jacob, M. R., Barker, K. S., Cleary, J. D., Walker, L. A., Nagle, D. G., & Clark, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306291200 · Cited by 204 · see citing works
Synergistic Antifungal Activities of Bafilomycin A 1 , Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans
Del Poeta, M., Cruz, M. C., Cardenas, M. E., Perfect, J. R., & Heitman, J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.739-746.2000 · Cited by 169 · see citing works
Quantitation of Candida albicans Ergosterol Content Improves the Correlation between In Vitro Antifungal Susceptibility Test Results and In Vivo Outcome after Fluconazole Treatment in a Murine Model of Invasive Candidiasis
Arthington-Skaggs, B. A., Warnock, D. W., & Morrison, C. J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2081-2085.2000 · Cited by 142 · see citing works
Abc1p Is a Multidrug Efflux Transporter That Tips the Balance in Favor of Innate Azole Resistance in Candida krusei
Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D. A., Niimi, K., Holmes, A. R., Niimi, M., & Cannon, R. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01095-08 · Cited by 100 · see citing works
The role of the cell wall in fungal pathogenesis
Arana, D. M., Prieto, D., Román, E., Nombela, C., Alonso‐Monge, R., & Pla, J. (2009) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2008.00070.x · Cited by 92 · see citing works
Genome-wide Mapping of the Coactivator Ada2p Yields Insight into the Functional Roles of SAGA/ADA Complex inCandida albicans
Sellam, A., Askew, C., Epp, E., Lavoie, H., Whiteway, M., & Nantel, A. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-11-1093 · Cited by 87 · see citing works
UPC2 Is Universally Essential for Azole Antifungal Resistance in Candida albicans
Vasicek, E. M., Berkow, E. L., Flowers, S. A., Barker, K. S., & Rogers, P. D. (2014) · Eukaryotic Cell · doi:10.1128/ec.00221-13 · Cited by 71 · see citing works
Changes in In Vitro Susceptibility Patterns of Aspergillus to Triazoles and Correlation With Aspergillosis Outcome in a Tertiary Care Cancer Center, 1999–2015
Heo, S. T., Tatara, A. M., Jiménez-Ortigosa, C., Jiang, Y., Lewis, R. E., Tarrand, J., Tverdek, F., Albert, N. D., Verweij, P. E., Meis, J. F., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix297 · Cited by 67 · see citing works
Self-citation
The multidrug transporter Pdr5 on the 25th anniversary of its discovery: an important model for the study of asymmetric ABC transporters
Golin, J., & Ambudkar, S. V. (2015) · Biochemical Journal · doi:10.1042/bj20150042 · Cited by 63 · see citing works
A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
Brand, S. R., Sobel, J. D., Nyirjesy, P., Ghannoum, M. A., Schotzinger, R. J., & Degenhardt, T. P. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1204 · Cited by 61 · see citing works
β-(1,3)-Glucan Unmasking in Some Candida albicans Mutants Correlates with Increases in Cell Wall Surface Roughness and Decreases in Cell Wall Elasticity
Hasim, S., Allison, D. P., Retterer, S. T., Hopke, A., Wheeler, R. T., Doktycz, M. J., & Reynolds, T. B. (2017) · Infection and Immunity · doi:10.1128/iai.00601-16 · Cited by 58 · see citing works
Inactivation of the FCY2 Gene Encoding Purine-Cytosine Permease Promotes Cross-Resistance to Flucytosine and Fluconazole in Candida lusitaniae
Chapeland-Leclerc, F., Bouchoux, J., Goumar, A., Chastin, C., Villard, J., & Noël, T. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3101-3108.2005 · Cited by 48 · see citing works
New Mechanisms of Flucytosine Resistance in C. glabrata Unveiled by a Chemogenomics Analysis in S. cerevisiae
Costa, C., Ponte, A., Pais, P., Santos, R., Cavalheiro, M., Yaguchi, T., Chibana, H., & Teixeira, M. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135110 · Cited by 46 · see citing works
In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey
Yenisehirli, G., Bulut, N., Yenisehirli, A., & Bulut, Y. (2015) · Jundishapur Journal of Microbiology · doi:10.5812/jjm.28057 · Cited by 42 · see citing works
The A395T Mutation in ERG11 gene confers fluconazole resistance in Candida tropicalis causing candidemia
Tan, J., Zhang, J., Chen, W., Sun, Y., Wan, Z., Li, R., & Liu, W. (2015) · Mycopathologia · doi:10.1007/s11046-014-9831-8 · Cited by 36 · see citing works
Evolutionary Dynamics of Candida albicans during In Vitro Evolution
Huang, M., McClellan, M., Berman, J., & Kao, K. C. (2011) · Eukaryotic Cell · doi:10.1128/ec.05168-11 · Cited by 34 · see citing works
Fluconazole susceptibility testing of Candida species by flow cytometry
Joung, Y. H., Kim, H. R., Lee, M. K., & Park, A. J. (2007) · Journal of Infection · doi:10.1016/j.jinf.2006.09.016 · Cited by 22 · see citing works
Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies
Sfeir, M. M., Jiménez-Ortigosa, C., Gamaletsou, M. N., Schuetz, A. N., Soave, R., Van Besien, K., Small, C. B., Perlin, D. S., & Walsh, T. J. (2020) · Journal of Fungi · doi:10.3390/jof6010020 · Cited by 19 · see citing works

Authors: Kontoyiannis, D. P., & Lewis, R. E.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
University of Houston (US)
Corresponding author: Kontoyiannis, Dimitrios P
ORCID: Kontoyiannis, Dimitrios P
Lewis, Russell E
Venue: The Lancet
Publisher: Elsevier BV
Published: 2002-03
Volume: 359
Issue: 9312
Pages: 1135-1144
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(02)08162-x
OpenAlex: W2135182325
Cited by: 553
References: 118
Citations by year: 2026: 4 · 2025: 7 · 2024: 8 · 2023: 22 · 2022: 9 · 2021: 14 · 2020: 22 · 2019: 15 · 2018: 19 · 2017: 25 · 2016: 31 · 2015: 23 · 2014: 23 · 2013: 28 · 2012: 21
FWCI: 5.29
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA-16672, P30CA016672)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
Keywords: antifungal resistance, fungal pathogens, resistance mechanisms, fungal epidemiology, fungal infection diagnosis, molecular mechanisms of resistance
MeSH terms: Antifungal Agents, Candida, Candidiasis, Humans, Microbial Sensitivity Tests, Mycoses, Drug Resistance, Fungal, Drug Resistance, Multiple, Fungal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antifungal drug resistance of pathogenic fungi

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks